It was a Tuesday evening. He reached for you — not dramatically, just a hand on your lower back while you were loading the dishwasher — and you felt nothing. Not annoyance. Not rejection. Just nothing. The place where a spark used to live was quiet. And you could not remember when it went quiet, only that it had.
You have already assigned this a story. We have been together too long. I am just tired. Maybe this is who I am at fifty-two. But those stories are incomplete. What happened to your desire has a mechanism — a physiological explanation that has nothing to do with your relationship, your attractiveness, or your worth. And once you understand that mechanism, the path forward becomes clearer.
This article is going to give you the full picture. Not just the biology, but the question that matters most: does this bother you? Because the answer to that question determines everything that follows.
What Actually Happened to Your Desire
Testosterone. This is the hormone most people associate with male sexual function, but it is the primary driver of sexual desire in women too. Women produce testosterone in the ovaries and adrenal glands, and levels decline gradually from the late 20s — roughly 1 to 2 percent per year. By the time you reach menopause, your testosterone is approximately half of what it was at its peak. In surgical menopause (removal of both ovaries), the drop is sudden and dramatic — up to 50 percent overnight. If your menopause was surgical, the drop in desire may have been sudden and disorienting. That is not a character flaw. It is physiology.
Estrogen. Estrogen does not drive desire directly, but it supports nearly everything that makes desire possible. It modulates dopamine — the neurotransmitter associated with wanting, anticipation, and reward. It supports serotonin pathways involved in mood. It maintains vaginal tissue health, and when that tissue becomes dry or painful, the body’s protective response is to shut down desire entirely — a pain-avoidance cycle that links directly to the dyspareunia covered in our guide to painful sex during menopause. When estrogen falls, the brain’s arousal response becomes harder to trigger and slower to build.
The dual control model. Your brain runs two competing systems for sexual response: an accelerator (excitatory) and a brake (inhibitory). Psychologist John Bancroft described this as the dual control model. In menopause, the accelerator weakens (less dopamine, less testosterone, less spontaneous desire) while the brake strengthens (stress, cortisol, pain, fatigue, body image shifts, disrupted sleep). The result is not that desire disappeared. It is that the balance shifted so far toward inhibition that desire cannot reach the threshold required to be felt.
Spontaneous desire arises without any external trigger — it appears on its own, often as an intrusive thought or urge. Responsive desire emerges in response to arousal that has already begun — through touch, connection, or erotic context. During menopause, many women shift from spontaneous to responsive desire. This is not a loss of desire. It is a change in how desire initiates. Understanding this shift can reduce distress and reframe expectations around sexual interest.
Sleep, cortisol, and context. Menopause disrupts sleep through night sweats, insomnia, and cortisol dysregulation. Chronic sleep loss directly suppresses testosterone. Elevated cortisol — from the stress of everything else menopause throws at you — further suppresses sexual hormones. Add body image changes, relationship fatigue, and the exhaustion of keeping up with a world that does not make space for what you are going through — and the inhibitory system has all the ammunition it needs.
This is not a verdict on who you are. It is a description of what happened in your body. And once you understand the mechanism, the options become clearer. If you want to understand the broader genitourinary syndrome of menopause framework that includes desire alongside dryness, pain, and urinary symptoms, start there.
Before We Talk About Treatment: The Distress Distinction
This section exists because most articles about low libido skip it. They assume you are here because you want your desire back. Maybe you do. But maybe you are here because you want to understand what happened — and understanding it is enough. Both are real. Both are valid.
Here is the clinical truth that matters: low desire without distress is not a disorder and does not require treatment. The diagnostic criteria for hypoactive sexual desire disorder — whether you use the DSM-5-TR classification (now called Female Sexual Interest/Arousal Disorder) or the ISSWSH clinical framework — require the presence of personal distress. A woman whose desire has shifted but who is not bothered by that shift does not have a condition that needs fixing.
Some women’s desire naturally changes during menopause, and for some, that change is not unwelcome. Maybe sex was always complicated. Maybe the pressure to want it was the actual burden, and its absence feels like relief. Maybe desire has simply shifted toward other forms of intimacy, connection, or solitude that feel more honest to who she is now. None of these responses are pathological. All of them are complete.
Do I miss wanting this for myself?
Is the absence of desire causing me distress?
If yes to either: the rest of this article is for you. The treatment section that follows offers a genuine evidence-based framework — not a sales pitch.
If no: that is a complete answer. You do not owe anyone a different one. Not your partner. Not your doctor. Not a culture that tells you desire should be permanent and constant. You can close this article and feel entirely fine about that — or keep reading out of curiosity. Either is welcome.
Notice what this section did not do. It did not imply that you should reconsider. It did not suggest that your partner’s needs make your answer incomplete. It did not frame your desire as existing for someone else’s benefit. Your desire belongs to you. What you do with this information is yours to decide.
What the Evidence Supports: Your Options
If you have decided this is something you want to address, here is what the research actually supports. I have organised these from most accessible to most clinical, because that is typically the order that makes sense for most women — start with what you can do now, and escalate if you need to.
Bonafide Ristela — The Non-Prescription Starting Point
This section contains an affiliate link. StillHer may earn a commission if you purchase through the link below. This does not affect our editorial recommendations or evidence assessment.
Ristela contains pycnogenol (French maritime pine bark extract), L-arginine, L-citrulline, and rose hip extract. These ingredients work through the nitric oxide pathway — enhancing blood flow to genital tissues during the sexual response. This is a vascular mechanism, not a hormonal one. Ristela does not contain hormones and does not have estrogen receptor activity.
I want to be honest about what the evidence shows. Ristela’s clinical trials primarily measured arousal, orgasm, and overall sexual function — not desire or libido as a central endpoint. Three RCTs totalling 263 women using the Lady Prelox formula (same active ingredients as Ristela) showed significant improvements in FSFI scores over 8 weeks: 60.8 percent improvement in overall sexual function versus 7.5 percent in placebo in the postmenopausal cohort (Bottari et al., Panminerva Med, 2012; n=83). Arousal, orgasm, and sexual satisfaction all improved significantly across the three trials.
So what does this mean for desire specifically? Ristela works on the physiological arousal pathway. For many women, easier arousal reconnects them to desire — once the body responds, the brain follows. For others, the issue sits deeper in the hormonal or psychological layers that Ristela does not directly address. If arousal is the missing piece, Ristela has the evidence to support trying it. If desire itself is absent regardless of arousal, other interventions may be more appropriate. For a full product review, see our Bonafide Ristela review.
Three RCTs, 263 total participants. Manufacturer-associated research. Primary endpoints were arousal and overall sexual function, not desire. Desire improvement is inferred rather than directly measured. No serious adverse events reported. Ristela addresses arousal and sexual function. It does not directly treat vaginal dryness or tissue atrophy.
Lifestyle Foundations — What Moves the Needle First
These are not replacements for treatment. They are the conditions under which treatment works better.
Exercise has moderate evidence for desire: aerobic exercise increases testosterone acutely, improves body image, lifts mood, and reduces cortisol. Even 30 minutes of moderate exercise three times per week has been associated with measurable improvement in sexual function scores. Sleep is bidirectional — poor sleep suppresses testosterone and desire, and low desire can disrupt sleep patterns. Addressing sleep disruption through menopause-specific strategies can itself improve desire. Stress reduction directly lowers cortisol, which suppresses testosterone production. Relationship communication — specifically non-demand pleasuring and reducing performance pressure around sex — has evidence for improving desire in long-term partnerships. Alcohol acutely lowers inhibition but chronically suppresses arousal and orgasm; cutting back often improves the very sexual function that the first glass seemed to help.
Mindfulness-Based Approaches
This surprised me when I found it in the research. Mindfulness-based cognitive therapy (MBCT) adapted for sexual dysfunction has genuine RCT evidence — and the effect sizes are large. In the DESIRE trial (Brotto et al., Journal of Consulting and Clinical Psychology, 2021; n=148), women with Female Sexual Interest/Arousal Disorder were randomised to 8-session group MBCT or supportive sex education. Both groups showed significant improvement in desire and arousal with large effect sizes (d = 1.29 to 1.60) maintained at 12-month follow-up. MBCT was superior on sexual distress reduction.
The mechanism: mindfulness retrains the brain’s attention system to notice erotic cues that the inhibitory system has been filtering out. It does not create desire from nothing — it reduces the noise that prevents desire from reaching awareness. In practice, MBCT for sexual dysfunction involves body-awareness exercises, interoception training, and cognitive restructuring around sexual self-concept. Evidence grade: moderate to strong (multiple RCTs, large effects, but relatively new research area).
Testosterone — The Strongest Evidence, Off-Label
Testosterone has the strongest evidence base for treating low desire in postmenopausal women. The 2019 Lancet meta-analysis (Islam et al.; 36 RCTs, over 8,400 women) found that transdermal testosterone significantly increased satisfying sexual events, desire, and arousal with an acceptable short-term safety profile.
There is no FDA-approved testosterone product for women. All testosterone prescriptions for women are off-label — using compounded formulations or male-formulated products at reduced doses. The ISSWSH 2021 Clinical Practice Guideline supports off-label transdermal testosterone for postmenopausal women with HSDD after comprehensive assessment. Long-term safety data beyond 24 months is limited. Women with a history of hormone-sensitive cancers should discuss individual risk with their oncologist before considering testosterone therapy.
If you are considering testosterone, your prescriber should be experienced in female sexual health and menopause medicine. Baseline and follow-up testosterone levels should be monitored. The goal is to restore testosterone to premenopausal physiological levels — not to exceed them. For women also experiencing vaginal dryness or pain, addressing those symptoms first (through vaginal moisturisers or non-hormonal GSM treatments) may improve desire on its own by removing the pain-avoidance brake.
Psychosexual Therapy
Relationship duration, unresolved conflict, emotional disconnection, and the accumulated weight of decades of caretaking can suppress desire independently of hormone levels. When this is the case, the right tool is not a supplement or a prescription. It is a skilled sex therapist or couples counsellor — ideally one with specific training in menopause-related sexual health.
This is not a last resort. It is not an admission of failure. It is an evidence-supported pathway that addresses the layer of desire that no product can reach. Psychosexual therapy for menopause-related desire loss typically involves sensate focus exercises, communication restructuring, and exploration of the sexual relationship in its current context — not its historical one. For further context on how menopause affects relationships, see our menopause and relationships guide.
What to Say to Your Doctor
Low libido is one of the menopause symptoms most likely to be dismissed — or never raised at all. Many women do not bring it up because they assume it is permanent, because they feel embarrassed, or because their previous experiences with clinicians taught them that sexual health at midlife is not taken seriously. Here is language that works.
- I would like to discuss my low libido as a menopause symptom. I have read that testosterone decline is a factor and would like to understand my options.
- Can we check my testosterone levels? I understand that levels alone do not diagnose desire disorders, but I would like a baseline before discussing treatment.
- I am experiencing both low desire and vaginal dryness. I would like to address both. Can we discuss a multimodal approach?
- Can you refer me to a menopause-certified provider or a sex therapist who specialises in menopause-related sexual health?
If your doctor dismisses the concern, you have the right to seek a provider who takes it seriously. The North American Menopause Society maintains a directory of NAMS-certified menopause practitioners. The ISSWSH also provides resources for finding sexual health specialists.
It Was Always Yours. It Still Is.
There are women reading this who have quietly accepted that desire is behind them. Who have not said it out loud to anyone — not their partner, not their closest friend, not their doctor. Who have absorbed the silence around this topic and interpreted it as confirmation that wanting is something you age out of.
That silence was wrong.
Desire changes during menopause. That is biology. But whether it returns, what form it takes, and whether you pursue it at all — those decisions belong to you. Not to the culture that made you invisible. Not to the medical system that dismissed you. Not to a partner whose needs do not override your own autonomy.
Your desire was always yours. It still is. And whatever you decide to do with this information — everything, something, or nothing at all — that decision is complete.